Cartesian Therapeutics (RNAC) Competitors

$7.39 +0.46 (+6.64%)

Closing price 04:00 PM Eastern

Extended Trading

$7.33 -0.06 (-0.87%)

As of 04:31 PM Eastern

RNAC vs. IVA, MGTX, GYRE, SLDB, and RLMD

Should you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Inventiva (IVA), MeiraGTx (MGTX), Gyre Therapeutics (GYRE), Solid Biosciences (SLDB), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical products" industry.

How does Cartesian Therapeutics compare to Inventiva?

Cartesian Therapeutics (NASDAQ:RNAC) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

: In the previous week, Cartesian Therapeutics had 6 more articles in the media than Inventiva. MarketBeat recorded 8 mentions for Cartesian Therapeutics and 2 mentions for Inventiva. Inventiva's average media sentiment score of 0.69 beat Cartesian Therapeutics' score of -0.35 indicating that Inventiva is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cartesian Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inventiva
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Cartesian Therapeutics presently has a consensus price target of $34.00, indicating a potential upside of 360.08%. Inventiva has a consensus price target of $16.56, indicating a potential upside of 205.45%. Given Cartesian Therapeutics' higher possible upside, equities analysts clearly believe Cartesian Therapeutics is more favorable than Inventiva.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cartesian Therapeutics
1 Sell rating(s)
0 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.67
Inventiva
1 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

3 Strong Buy rating(s)
3.10
: Cartesian Therapeutics has higher earnings, but lower revenue than Inventiva.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cartesian Therapeutics $1.78M 122.33 -$130.30M -$5.90 N/A
Inventiva $4.48M 176.46 -$400.67M N/A N/A
: Inventiva has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%.
Company Net Margins Return on Equity Return on Assets
Cartesian Therapeutics -8,550.65% N/A -28.25%
Inventiva N/A N/A N/A
: Cartesian Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.
: 86.9% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 60.3% of Cartesian Therapeutics shares are held by insiders. Comparatively, 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inventiva	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$1.78M	122.33	-$130.30M	-$5.90	N/A
Inventiva	$4.48M	176.46	-$400.67M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
Inventiva	N/A	N/A	N/A

Summary

Inventiva beats Cartesian Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Cartesian Therapeutics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

: In the previous week, Cartesian Therapeutics had 6 more articles in the media than MeiraGTx. MarketBeat recorded 8 mentions for Cartesian Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.00 beat Cartesian Therapeutics' score of -0.35 indicating that MeiraGTx is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MeiraGTx
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cartesian Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are owned by institutional investors. 7.5% of MeiraGTx shares are owned by company insiders. Comparatively, 60.3% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: MeiraGTx currently has a consensus price target of $25.67, suggesting a potential upside of 163.25%. Cartesian Therapeutics has a consensus price target of $34.00, suggesting a potential upside of 360.08%. Given Cartesian Therapeutics' higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than MeiraGTx.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MeiraGTx
1 Sell rating(s)
1 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.75
Cartesian Therapeutics
1 Sell rating(s)

0 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.67
: MeiraGTx has a net margin of -140.31% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat MeiraGTx's return on equity.
Company Net Margins Return on Equity Return on Assets
MeiraGTx -140.31% -1,065.47% -53.33%
Cartesian Therapeutics -8,550.65% N/A -28.25%
: MeiraGTx has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.
: MeiraGTx has higher revenue and earnings than Cartesian Therapeutics. MeiraGTx is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MeiraGTx $81.39M 9.76 -$114.20M -$1.42 N/A
Cartesian Therapeutics $1.78M 122.33 -$130.30M -$5.90 N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cartesian Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-140.31%	-1,065.47%	-53.33%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	9.76	-$114.20M	-$1.42	N/A
Cartesian Therapeutics	$1.78M	122.33	-$130.30M	-$5.90	N/A

Summary

MeiraGTx and Cartesian Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

: In the previous week, Cartesian Therapeutics had 6 more articles in the media than Gyre Therapeutics. MarketBeat recorded 8 mentions for Cartesian Therapeutics and 2 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.00 beat Cartesian Therapeutics' score of -0.35 indicating that Gyre Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gyre Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cartesian Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are owned by institutional investors. 10.0% of Gyre Therapeutics shares are owned by company insiders. Comparatively, 60.3% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Gyre Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 118.51%. Cartesian Therapeutics has a consensus price target of $34.00, suggesting a potential upside of 360.08%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than Gyre Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gyre Therapeutics
2 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.00
Cartesian Therapeutics
1 Sell rating(s)

0 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.67
: Gyre Therapeutics has a net margin of 4.31% compared to Cartesian Therapeutics' net margin of -8,550.65%. Gyre Therapeutics' return on equity of 10.85% beat Cartesian Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Gyre Therapeutics 4.31% 10.85% 9.16%
Cartesian Therapeutics -8,550.65% N/A -28.25%
: Gyre Therapeutics has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.
: Gyre Therapeutics has higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gyre Therapeutics $116.59M 6.47 $5.03M $0.01 778.00
Cartesian Therapeutics $1.78M 122.33 -$130.30M -$5.90 N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cartesian Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	4.31%	10.85%	9.16%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	6.47	$5.03M	$0.01	778.00
Cartesian Therapeutics	$1.78M	122.33	-$130.30M	-$5.90	N/A

Summary

Gyre Therapeutics beats Cartesian Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

: Cartesian Therapeutics has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Solid Biosciences N/A N/A -$174.32M -$2.02 N/A
Cartesian Therapeutics $1.78M 122.33 -$130.30M -$5.90 N/A
: In the previous week, Cartesian Therapeutics had 6 more articles in the media than Solid Biosciences. MarketBeat recorded 8 mentions for Cartesian Therapeutics and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.64 beat Cartesian Therapeutics' score of -0.35 indicating that Solid Biosciences is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Solid Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cartesian Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are owned by institutional investors. 1.9% of Solid Biosciences shares are owned by company insiders. Comparatively, 60.3% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: Solid Biosciences has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Solid Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Solid Biosciences N/A -72.23% -59.27%
Cartesian Therapeutics -8,550.65% N/A -28.25%
: Solid Biosciences currently has a consensus price target of $16.09, suggesting a potential upside of 133.20%. Cartesian Therapeutics has a consensus price target of $34.00, suggesting a potential upside of 360.08%. Given Cartesian Therapeutics' higher probable upside, analysts clearly believe Cartesian Therapeutics is more favorable than Solid Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solid Biosciences
1 Sell rating(s)
0 Hold rating(s)

11 Buy rating(s)

1 Strong Buy rating(s)
2.92
Cartesian Therapeutics
1 Sell rating(s)

0 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.67
: Solid Biosciences has a beta of 2.47, indicating that its stock price is 147% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$2.02	N/A
Cartesian Therapeutics	$1.78M	122.33	-$130.30M	-$5.90	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cartesian Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-72.23%	-59.27%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Cartesian Therapeutics beats Solid Biosciences on 9 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

: Relmada Therapeutics has higher earnings, but lower revenue than Cartesian Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Relmada Therapeutics N/A N/A -$57.38M -$1.45 N/A
Cartesian Therapeutics $1.78M 122.33 -$130.30M -$5.90 N/A
: In the previous week, Cartesian Therapeutics had 6 more articles in the media than Relmada Therapeutics. MarketBeat recorded 8 mentions for Cartesian Therapeutics and 2 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.00 beat Cartesian Therapeutics' score of -0.35 indicating that Relmada Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Relmada Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cartesian Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 60.3% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: Relmada Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Relmada Therapeutics N/A -170.83% -145.58%
Cartesian Therapeutics -8,550.65% N/A -28.25%
: Relmada Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 63.27%. Cartesian Therapeutics has a consensus price target of $34.00, suggesting a potential upside of 360.08%. Given Cartesian Therapeutics' higher probable upside, analysts clearly believe Cartesian Therapeutics is more favorable than Relmada Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relmada Therapeutics
1 Sell rating(s)
1 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
2.71
Cartesian Therapeutics
1 Sell rating(s)

0 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.67
: Relmada Therapeutics has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.45	N/A
Cartesian Therapeutics	$1.78M	122.33	-$130.30M	-$5.90	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cartesian Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-170.83%	-145.58%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Cartesian Therapeutics beats Relmada Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Cartesian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNAC vs. The Competition

Export

Metric	Cartesian Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$217.13M	$3.40B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-1.25	38.85	29.04	28.48
Price / Sales	122.33	155.54	476.48	60.89
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	-1.52	7.03	9.67	6.67
Net Income	-$130.30M	$23.62M	$3.55B	$332.64M
7 Day Performance	8.68%	3.67%	1.70%	2.01%
1 Month Performance	18.05%	7.17%	5.62%	9.19%
1 Year Performance	-40.59%	67.04%	34.42%	39.59%

Cartesian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNAC Cartesian Therapeutics	1.9126 of 5 stars	$7.39 +6.6%	$34.00 +360.1%	N/A	$217.13M	$1.78M	N/A	64	Earnings Report
IVA Inventiva	3.0369 of 5 stars	$5.01 -2.3%	$16.56 +230.5%	N/A	$748.73M	$5.07M	N/A	100
MGTX MeiraGTx	2.8434 of 5 stars	$9.08 -0.5%	$25.67 +182.7%	N/A	$743.60M	$81.39M	N/A	300	Upcoming Earnings
GYRE Gyre Therapeutics	1.3792 of 5 stars	$7.67 +0.5%	$17.00 +121.6%	N/A	$740.06M	$116.59M	767.77	40	News Coverage Upcoming Earnings
SLDB Solid Biosciences	3.3321 of 5 stars	$7.45 -0.7%	$16.09 +116.0%	N/A	$738.10M	N/A	N/A	100	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNAC) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cartesian Therapeutics (RNAC) Competitors

RNAC vs. IVA, MGTX, GYRE, SLDB, and RLMD

How does Cartesian Therapeutics compare to Inventiva?

Summary

How does Cartesian Therapeutics compare to MeiraGTx?

Summary

How does Cartesian Therapeutics compare to Gyre Therapeutics?

Summary

How does Cartesian Therapeutics compare to Solid Biosciences?

Summary

How does Cartesian Therapeutics compare to Relmada Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC vs. The Competition

Cartesian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cartesian Therapeutics (RNAC) Competitors

RNAC vs. IVA, MGTX, GYRE, SLDB, and RLMD

How does Cartesian Therapeutics compare to Inventiva?

Summary

How does Cartesian Therapeutics compare to MeiraGTx?

Summary

How does Cartesian Therapeutics compare to Gyre Therapeutics?

Summary

How does Cartesian Therapeutics compare to Solid Biosciences?

Summary

How does Cartesian Therapeutics compare to Relmada Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC vs. The Competition

Cartesian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools